These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer. Fink CA; Buchele C; Baumann L; Liermann J; Hoegen P; Ristau J; Regnery S; Sandrini E; König L; Rippke C; Bonekamp D; Schlemmer HP; Debus J; Koerber SA; Klüter S; Hörner-Rieber J Front Oncol; 2024; 14():1308406. PubMed ID: 38425342 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk. Schneiders FL; van Vliet C; Giraud N; Bruynzeel AME; Slotman BJ; Palacios MA; Senan S Clin Transl Radiat Oncol; 2023 Nov; 43():100680. PubMed ID: 37808454 [TBL] [Abstract][Full Text] [Related]
12. On the pitfalls of PTV in lung SBRT using type-B dose engine: an analysis of PTV and worst case scenario concepts for treatment plan optimization. Leung RWK; Chan MKH; Chiang CL; Wong M; Blanck O Radiat Oncol; 2020 May; 15(1):130. PubMed ID: 32471457 [TBL] [Abstract][Full Text] [Related]
13. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360 [TBL] [Abstract][Full Text] [Related]
14. Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors. Baumann R; Chan MKH; Pyschny F; Stera S; Malzkuhn B; Wurster S; Huttenlocher S; Szücs M; Imhoff D; Keller C; Balermpas P; Rades D; Rödel C; Dunst J; Hildebrandt G; Blanck O Front Oncol; 2018; 8():171. PubMed ID: 29868486 [TBL] [Abstract][Full Text] [Related]
15. Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy. Rabe M; Palacios MA; van Sörnsen de Koste JR; Eze C; Hillbrand M; Belka C; Landry G; Senan S; Kurz C Med Phys; 2023 May; 50(5):2625-2636. PubMed ID: 36810708 [TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553 [TBL] [Abstract][Full Text] [Related]
18. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498 [TBL] [Abstract][Full Text] [Related]
19. Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. Mayinger M; Ludwig R; Christ SM; Dal Bello R; Ryu A; Weitkamp N; Pavic M; Garcia Schüler H; Wilke L; Guckenberger M; Unkelbach J; Tanadini-Lang S; Andratschke N Radiat Oncol; 2021 May; 16(1):84. PubMed ID: 33947429 [TBL] [Abstract][Full Text] [Related]